Vacc-CRX with neutralizing properties constitutes the 3 rd cornerstone of Bionor’s HIV program
Oslo, February 7, 2019 The recent Proof of Mechanism shown for Vacc-CRX demonstrates the dynamic properties of this product obstructing both of the well-known virus entry mechanisms CCR5 and CXCR4 […]
Bionor’s 3rd vaccine candidate, Vacc-CRX, Proof of Mechanism established
Oslo, January 23, 2019. Bionor is pleased to announce that Proof of Mechanism is established for our 3rd vaccine candidate, Vacc-CRX. This product aims to prevent binding between gp120 V3 […]
Bionor has acquired its 3rd HIV vaccine candidate, Vacc-CRX.
Oslo, January 10, 2019 The acquisition is in the form of an exchange of patents and rights between Bionor and Immunor AS. During Bionor’s equity raise in December 2017, Bionor […]